Cookie Consent by FreePrivacyPolicy.com
genekam logo
  • usa
    • german
    • russia
    • china
Duissernstr. 65a · 47058 Duisburg · Germany
Tel. +49 203 / 555 858 -31 / 32 / 33 · Fax: +49 203 / 35 82 99
menuicon
slider
Latest News:

09.11.2023
Genekam to attend BIO CEO & Investor Conference
February 26-27, 2024 | New York

Latest News:

04.05.2023
Genekam registered with EUDAMED - A step towards meeting the latest IVDR requirements!

  • LSX World conference

    Genekam is to attend LSX World conference 29-30 April, 2024, Business Design Center, London, UK

  • MEDICA 2024

    Visit us on Medica Duesseldorf, 11.-14. November 2024

Antibody Conjugate Therapy

Genekam is developing complex solutions based on antibody conjugates for therapeutic and diagnostic use. The antibodies can be recombinant as well as monoclonal type. Conjugates will be based on beyond the state of art technology. Some of conjugates may have potential to be used as vaccines also.

TOP